Saturday, May 31, 2008
Words are flowing out like endless rain into a paper cup,
They slither while they pass they slip away across the universe
Pools of sorrow, waves of joy are drifting through my open mind,
Possessing and caressing me.
Jai guru de va om
Nothing's gonna change my world,
Nothing's gonna change my world.
Nothing's gonna change my world,
Nothing's gonna change my world.
Thursday, May 29, 2008
Sometimes I buy a stock because of the chart, sometimes it is because of a good story and sometimes it is because of compelling fundamentals. Rarely do all three of these criteria come together at the same time.
Solar stocks have for the most part great looking charts. The story is equally impressive in light of high oil prices and the Alternative Energy party likely to capture the House, Senate and maybe even the White House in November.
Now the really cool part:
JASO as a forward PE of 15, Quarterly Revenue Growth of 235% and Quarterly Earnings Growth of 155%.
SOLF has a forward PE of 3, Quarterly Revenue Growth of 304% and Quarterly Earnings Growth of 101%.
TSL has a forward PE of 12, Quarterly Earnings Growth of 161% and Quarterly Earnings Growth of 242%.
Take Away: Solar is a lot more then just Momentum Stocks of the Day, these are emerging superstars backed by real revenues, earnings and growth.
Wednesday, May 28, 2008
Wednesday May 28, 7:00 am ET
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), said that it has signed or has in attorney-review non-disclosure agreements with major pharmaceutical companies to enable further discussions regarding the Company’s nanoviricide drug candidate against Epidemic Kerato-Conjunctivitis (EKC). “We have already scheduled meetings to discuss the results of our recent animal studies against EKC,” said Eugene Seymour, MD, MPH, CEO of the Company, adding, “We have significant interest from several large pharma companies in both USA and abroad.”
Tuesday, May 27, 2008
That was my daughter's senior paper, Power Point presentation and all, Ken Kesey, Timothy Leary, The Doors, Dylan, Ginsberg, Woodstock...........without a doubt, her father's daughter.
But that's not what I mean by Generation of Power. Instead, I am referring to two low priced power generation stocks with bullish charts:
DESC: Distributed Energy @ $0.48
BCON: Beacon Power @ $1.55
I'm in them for a short term play, maybe longer if they act right.
Saturday, May 17, 2008
In a world moves in mysterious ways kind of miracle, that geographical distance brought us closer together then either one of us could ever have imagined. Family, that once meant so little, now means so much. One of the most wonderful benefits of the communications revolution of the past decade, the computer, the instant messages, the cell phones, text messages and sharing of even the most ordinary in our day-to day lives has kept us together while we have been apart.
So where I once labored under the torment of missing the final years of both my daughters' adolescence, it is apparent that I missed only the most cursory observations of their passing into adulthood. The growth of a child that is real, tangible, felt and forever, growth that manifests as the unfolding into maturity, of that wonder I have not missed a beat.
As for the fear of the parent of the time when their child is all grown up, I have learned that they are never all grown up. As with my parents and me, from the time of a child's emergence into the world, through the entire adventure that takes place along the continuum of days, weeks and years that follow, parent and child share a destiny of love, one that never grows up, never leaves home and with which we are never without.
Now the time has come to pack up the computer and head out the door for yet another milestone, in her life and in mine.
Wednesday, May 14, 2008
A broad spectrum virivide and its application as a novel human anti-viral therapeutic system.
E. Seymour, A. Diwan, V. Boniuk, R. Barton
NanoViricides, Inc., US
nanomedicine, antivirals, therapeutics, H5N1
A new class of therapeutic anti-virals has been created utilizing the principles of nanotechnology. A broad-spectrum targeting molecule (ligand) is chemically attached to a polymer-derived nano-structure. Attachment to the viral particle via the sialic acid attachment system is accomplished. The envelope of the targeted viral particle is then destroyed. The now non-infectious genomic material escapes and is then destroyed by the cells of the immune system. Studies have been performed on animals infected with rabies, H5N1, human influenza, HIV, dengue, Ebola and the virus that causes epidemic keratoconjunctivitis. These studies have been done by various US government medical research agencies. Results of these studies and their implications for human anti-viral treatments will be discussed.
Saturday, May 10, 2008
What they have is a "cure-all" for an estimated 90% of all viral disease.
The drugs of NanoViricides are NOT VACCINES, but rather are anti-viral agents that directly attack virus particles in the bloodstream. The drugs contain unique nano structures that bind with virus particles (and only with virus particles) and physically pull them apart and destroy them (the company's web site has an electron microscope image of this process taking place).
The treatments of NanoViricides do not make use of, or even require the presence of a functioning immune system in the host animal. Again, these drugs are NOT VACCINES, but rather are direct CURES for viral disease.
It so happens that the drugs of this company are very broad spectrum across many viral diseases, and do not have to be specifically targeted relative to strains or mutations. Unlike bacteria, there are no viruses that are beneficial for or symbiotic with the functioning of the human body, so there's never an issue of having to limit the spectrum of effect, or the need to design a drug to kill some viruses while not harming others.
The nano materials are created from natural materials which are otherwise inert and ignored by the human body, and eventually are filtered out of the bloodstream in a few weeks time.
This treatment is truly revolutionary, unlike any approach that has ever been brought to medical science. If successful, the drugs of NanoViricides will be for the treatment and cure of viral disease what Penicillin was 80 years ago for the treatment and cure of bacterial disease.
All this being said... there are significant hurdles still to pass regarding testing and approval, and the possibility exists for failure. However, in all previous tests both in vitro and in vivo, the treatments of NanoViricides have shown significant efficacy against a multitude of viral diseases, and have never elicited any side effects. With each reported successes of a pre-clinical animal trial, the probability that the approach will eventually fail or need to be discarded seems all the more remote.
The company currently has studies in progress (or about to begin) for their treatments for Ebola, HIV, Dengue Fever, H5N1, Human Flu, EKC (Epidemic Keratoconjunctivitis), and others. Recent published successes with Ebola and HIV have propelled the share price over 300% so far this calendar year, and results from additional drug treatment trials relative to these and other diseases are expected in the coming weeks.
The CEO of the company, Dr. Eugene Seymour, projects that in five years, if all continues to go well, NanoViricides could have five or more drugs fully approved and on the market, each with revenues of one billion dollars. With a current share price of $1.30, the market cap of NanoViricides is now roughly $150M, which is about one five hundredth (1/500th) of the market cap of Merck. If one assumes that a bio tech company with approved proprietary drugs to cure most viral disease would end up with a market cap of one fifth that of Merck, that would project eventual price for NNVC stock to be well over $100 a share. If market cap eventually EQUALS that of Merck, then the share price could reach $500 a share (pre split).
Great discussions over on Investors Hub.
Monday, May 05, 2008
Positive Initial Results Pave the Way for Definitive Follow-Up Studies
Should be only the beginning.
Saturday, May 03, 2008
My bad, I should have told all of you. I have been asked to help coach the Detroit Red Wings during the Stanley Cup playoffs.
I know what you are thinking, "What good can he do them in Arizona?"
Well the obvious answer if often the correct one:
Karma knows no geographical bounds.
Sitting here in the desert in front of my TV, I am as helpful as if I was standing behind the bench. Plus, management was concerned that my presence in the locker room would be a distraction. So I have been communicating through our private chat facility.
As for the money to be made, you should have already cleaned up on the solar stocks if you were trading them and if you were buying and holding them, the best is yet to come.
But the big winner in the weeks ahead is going to be Nanoviricides. Reports from at least three research studies are due this month, but the biggie, the one that will cause you all to remember me and this Blog for the rest of your lives, is due a little later in June, or maybe July. That's the HIV study.
If this is not enough to keep everyone busy in front of their computers, my latest idea is to short the agriculture stocks, you know, recent parabolic freaks that include POT, AGU and DE.
If you remember what happened to Google earlier this year, or the financial stocks, it appears now to be Agriculture's time at the salon.
Well, guess what.......Philadelphia just eliminated Montreal from the playoffs. Looks like the Red Wings will be needing my scouting of the Flyers now. Amazing, an all Pennsylvania Eastern Conference Final.
I love this job.